Redeye is encouraged by Integrum’s strong quarterly sales, and we argue that the company seems to continue delivering well on its intensified US commercial efforts. We make no particular estimate changes but increase our WACC due to a higher risk-free rate, somewhat negatively affecting our fair value range.